Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496240 | 0.85 | UGT2B7 (0.53) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL7502070 | 0.82 | UGT2B7 (0.50) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL16684715 | 0.82 | UGT2B7 (0.59) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL5401290 | 0.82 | UGT2B7 (0.59) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL30717250 | 0.80 | TAAR1 (0.57) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL6678170 | 0.80 | ABCB11 (0.66) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL6678168 | 0.80 | UGT2B7 (0.57) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL1984485 | 0.80 | TAAR1 (0.57) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL13646401 | 0.80 | UGT2B7 (0.57) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 | |
| SCHEMBL2096230 | 0.79 | UGT2B7 (0.52) | UGT2B7CYP2D6MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| CN-118339204-A | Dual catalyst composition | 道达尔能源一技术比利时公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118339205-A | Polymerization process using dual catalyst composition | 道达尔能源一技术比利时公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118317983-A | Dual catalyst composition | 道达尔能源一技术比利时公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240216291-A1 | Nucleic Acid Containing Nanoparticles | BIO TRIP B V (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240209195-A1 | PROCESS TO PRODUCE AN ADDITIVED COMPOSITION OF POLYETHYLENE COMPRISING POST-CONSUMER RESIN AND CAPS OR CLOSURES MADE FROM THIS COMPOSITION | TOTALENERGIES ONETECH BELGIUM (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240209127-A1 | NEW METALLOCENE CATALYST AND USE THEREOF | TOTALENERGIES ONETECH BELGIUM (BE) | 2024-06-27 | — | — | US | disclosed |
| EP-3110537-B1 | USE OF INORGANIC MEMBRANES GRAFTED WITH ORGANIC MOIETIES FOR INCREASING FOULING RESISTANCE | VITO NV (BE) | 2024-06-12 | — | — | EP | disclosed |
| EP-4358936-A1 | NUCLEIC ACID CONTAINING NANOPARTICLES | Bio-TRIP B.V. (NL) | 2024-05-01 | — | — | EP | disclosed |
| EP-4347667-A1 | NEW METALLOCENE CATALYST AND USE THEREOF | TotalEnergies OneTech Belgium (BE) | 2024-04-10 | — | — | EP | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0733364-A1 | MEDICINAL COMPOSITION FOR CIRCULATORY ORGAN | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-25 | — | — | EP | disclosed |
| CN-1105354-A | Novel alkamine derivative and slat of same | YAMANOUCHI PHARMA CO LTD (JP) | 1995-07-19 | — | — | CN | disclosed |
| CN-1051178-A | New heterogeneous ring compound and preparation method thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1991-05-08 | — | — | CN | disclosed |
| EP-0425134-A1 | Condensed pyrrolo derivatives, process for their preparation and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| US-4104036-A | TO IMPROVE OCTANE RATING | ATLANTIC RICHFIELD COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | KLK3, FOLH1, CA14 | UGT2B7 3715/4885CYP2D6 4205/4885MEN1 81/4885 |
| US-20240216291-A1 | Nucleic Acid Containing Nanoparticles | APOB, APOL1, TLR3 | UGT2B7 4592/4885CYP2D6 4426/4885MEN1 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.